Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 2/20 | 0.47 |
| ▸ | IGF1R | P08069 | 1/20 | 0.39 |
| ▸ | NPEPPS | P55786 | 2/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | GCK | P35557 | 1/20 | 0.36 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.35 |
| ▸ | ACVR1 | Q04771 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.34 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3931997 | 0.86 | NUDT1 (0.51) | NUDT1JAK2KDM4ESMN1; SMN2MAP4K1 | |
| SCHEMBL3920643 | 0.86 | NUDT1 (0.50) | NUDT1JAK2KDM4ESMN1; SMN2ACVR1 | |
| SCHEMBL3922898 | 0.85 | NUDT1 (0.47) | NUDT1JAK2MAP4K1ACVR1ALDH1A1 | |
| SCHEMBL3920013 | 0.84 | NUDT1 (0.46) | NUDT1MAP4K1ACVR1MAPK8 | |
| SCHEMBL3935022 | 0.84 | NUDT1 (0.46) | NUDT1JAK2MAP4K1ACVR1ALDH1A1 | |
| SCHEMBL3921271 | 0.84 | NUDT1 (0.55) | NUDT1IGF1RJAK2KDM4EHSD17B10 | |
| SCHEMBL3922752 | 0.83 | NUDT1 (0.48) | NUDT1JAK2MAP4K1ACVR1ALDH1A1 | |
| SCHEMBL3921893 | 0.83 | NUDT1 (0.53) | NUDT1IGF1RJAK2KDM4EHSD17B10 | |
| SCHEMBL3927139 | 0.83 | NUDT1 (0.53) | NUDT1IGF1RJAK2KDM4EHSD17B10 | |
| Hydrochloric Acid SCHEMBL3926115 | 0.82 | NUDT1 (0.52) | NUDT1IGF1RJAK2KDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2051980-B1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-02-26 | — | — | EP | disclosed |
| US-7531539-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-05-12 | — | — | US | disclosed |
| US-20080045496-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045496-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | JAK2, NTRK2, NTRK3 | NUDT1 4271/4885IGF1R 556/4885NPEPPS 2934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.